Epigenetic reprogramming by tumor-derived EZH2 gain-offunction mutations promotes aggressive 3D cell morphologies and enhances melanoma tumor growth

Oncotarget

Volumn 6, Issue 5, 2015, Pages 2928-2938

  Barsotti, Anthony M ^a   Ryskin, Michael ^a   Zhong, Wenyan ^a   Zhang, Wei Guo ^a   Giannakou, Andreas ^a   Loreth, Christine ^a   Diesl, Veronica ^a   Follettie, Maximillian ^a   Golas, Jonathon ^a   Lee, Michelle ^a   Nichols, Timothy ^a   Fan, Conglin ^a   Li, Gang ^a   Dann, Stephen ^a   Fantin, Valeria R ^a   Arndt, Kim ^a   Verhelle, Dominique ^a   Rollins, Robert A ^a  

^a PFIZER INC   (United States)

Author keywords

3D culture; Axonal guidance; Cancer epigenetics; EZH2; EZH2 mutations; Melanoma; Motility

Indexed keywords

HISTONE H3; TRANSCRIPTION FACTOR EZH2; ENZYME INHIBITOR; EZH2 PROTEIN, HUMAN; HISTONE DEMETHYLASE; KDM6B PROTEIN, HUMAN; POLYCOMB REPRESSIVE COMPLEX 2;

A375 CELL LINE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CARCINOGENESIS; CELL CONTRACTION ASSAY; CELL MIGRATION; CELL MOTILITY; CELL SHAPE; CELL STRUCTURE; CONTROLLED STUDY; CUTANEOUS MELANOMA; EPIGENETICS; FEMALE; GAIN OF FUNCTION MUTATION; GENE EXPRESSION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; ANIMAL; CELL LINE; CELL MOTION; CELL PROLIFERATION; DNA METHYLATION; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; MELANOMA; METABOLISM; MOLECULARLY TARGETED THERAPY; MUTATION; NUDE MOUSE; PATHOLOGY; SKIN NEOPLASMS; TUMOR INVASION; TUMOR VOLUME;

ANIMALS; CELL LINE; CELL MOVEMENT; CELL PROLIFERATION; CELL SHAPE; DNA METHYLATION; ENZYME INHIBITORS; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; JUMONJI DOMAIN-CONTAINING HISTONE DEMETHYLASES; MELANOMA; MICE, NUDE; MOLECULAR TARGETED THERAPY; MUTATION; NEOPLASM INVASIVENESS; POLYCOMB REPRESSIVE COMPLEX 2; SKIN NEOPLASMS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84923308494     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2758     Document Type: Article

References (48)

1. Dawson MA, Kouzarides T. Cancer epigenetics: from mechanism to therapy. Cell. 2012; 150:12-27.
2. Rodriguez-Paredes M, Esteller M. Cancer epigenetics reaches mainstream oncology. Nature medicine. 2011; 17:330-339.
3. Sparmann A, van Lohuizen M. Polycomb silencers control cell fate, development and cancer. Nature Reviews Cancer. 2006; 6:846-856.
4. Ringrose L, Paro R. Epigenetic regulation of cellular memory by the Polycomb and Trithorax group proteins. Annual Review of Genetics. 2004; 38:413-443.
5. Sauvageau M, Sauvageau G. Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell. 2010; 7:299-313.
6. Chang CJ, Hung MC. The role of EZH2 in tumour progression. British Journal of Cancer. 2012; 106:243-247.
7. Shen L, Cui J, Liang S, Pang Y, Liu P. Update of research on the role of EZH2 in cancer progression. OncoTargets and Therapy. 2013; 6:321-324.
8. Morin RD, Johnson NA, Severson TM, Mungall AJ, An J, Goya R, Paul JE, Boyle M, Woolcock BW, Kuchenbauer F, Yap D, Humphries RK, Griffith OL, Shah S, Zhu H, Kimbara M, et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nature Genetics. 2010; 42:181-185.
9. Bodor C, Grossmann V, Popov N, Okosun J, O'Riain C, Tan K, Marzec J, Araf S, Wang J, Lee AM, Clear A, Montoto S, Matthews J, Iqbal S, Rajnai H, Rosenwald A, et al. EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood. 2013; 122:3165-3168.
10. Yap DB, Chu J, Berg T, Schapira M, Cheng SW, Moradian A, Morin RD, Mungall AJ, Meissner B, Boyle M, Marquez VE, Marra MA, Gascoyne RD, Humphries RK, Arrowsmith CH, Morin GB, et al. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood. 2011; 117:2451-2459.
11. Sneeringer CJ, Scott MP, Kuntz KW, Knutson SK, Pollock RM, Richon VM, Copeland RA. Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proceedings of the National Academy of Sciences of the United States of America. 2010; 107:20980-20985.
12. McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, Liu Y, Graves AP, Della Pietra A, 3rd, Diaz E, LaFrance LV, Mellinger M, Duquenne C, Tian X, Kruger RG, McHugh CF, et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. 2012; 492:108-112.
13. Knutson SK, Wigle TJ, Warholic NM, Sneeringer CJ, Allain CJ, Klaus CR, Sacks JD, Raimondi A, Majer CR, Song J, Scott MP, Jin L, Smith JJ, Olhava EJ, Chesworth R, Moyer MP, et al. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nature Chemical Biology. 2012; 8:890-896.
14. Qi W, Chan H, Teng L, Li L, Chuai S, Zhang R, Zeng J, Li M, Fan H, Lin Y, Gu J, Ardayfio O, Zhang JH, Yan X, Fang J, Mi Y, et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109:21360-21365.
15. Hodis E, Watson IR, Kryukov GV, Arold ST, Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Place C, Dicara D, Ramos AH, Lawrence MS, Cibulskis K, Sivachenko A, Voet D, et al. A landscape of driver mutations in melanoma. Cell. 2012; 150:251-263.
16. Tiffen J, Gallagher SJ, Hersey P. EZH2: An emerging role in melanoma biology and strategies for targeted therapy. Pigment cell & Melanoma Research. 2014; (Epub June 10th).
17. Majer CR, Jin L, Scott MP, Knutson SK, Kuntz KW, Keilhack H, Smith JJ, Moyer MP, Richon VM, Copeland RA, Wigle TJ. A687V EZH2 is a gain-offunction mutation found in lymphoma patients. FEBS Letters. 2012; 586:3448-3451.
18. Ott HM, Graves A, Pappalardi MB, Huddleston M, Halsey WS, Hughes A, Groy A, Dul E, Jiang Y, Bai Y, Annan R, Verma S, Knight SD, Kruger RG, Dhanak D, Schwartz B, et al. A687V EZH2 is a driver of histone H3 lysine 27 (H3K27) hyper-trimethylation. Molecular Cancer Therapeutics. 2014; 13:3062-3073.
19. Caramel J, Papadogeorgakis E, Hill L, Browne GJ, Richard G, Wierinckx A, Saldanha G, Osborne J, Hutchinson P, Tse G, Lachuer J, Puisieux A, Pringle JH, Ansieau S, Tulchinsky E. A switch in the expression of embryonic EMT-inducers drives the development of malignant melanoma. Cancer Cell. 2013; 24:466-480.
20. Tan JL, Ravid S, Spudich JA. Control of nonmuscle myosins by phosphorylation. Annual Review of Biochemistry. 1992; 61:721-759.
21. Tiwari N, Tiwari VK, Waldmeier L, Balwierz PJ, Arnold P, Pachkov M, Meyer-Schaller N, Schubeler D, van Nimwegen E, Christofori G. Sox4 is a master regulator of epithelial-mesenchymal transition by controlling Ezh2 expression and epigenetic reprogramming. Cancer Cell. 2013; 23:768-783.
22. Ren G, Baritaki S, Marathe H, Feng J, Park S, Beach S, Bazeley PS, Beshir AB, Fenteany G, Mehra R, Daignault S, Al-Mulla F, Keller E, Bonavida B, de la Serna I, Yeung KC. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer. Cancer Research. 2012; 72:3091-3104.
23. Cao Q, Yu J, Dhanasekaran SM, Kim JH, Mani RS, Tomlins SA, Mehra R, Laxman B, Cao X, Yu J, Kleer CG, Varambally S, Chinnaiyan AM. Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene. 2008; 27:7274-7284.
24. Amatangelo MD, Garipov A, Li H, Conejo-Garcia JR, Speicher DW, Zhang R. Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition. Cell Cycle. 2013; 12:2113-2119.
25. Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA, Salvesen HB, Otte AP, Akslen LA. EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. Journal of clinical oncology: Official Journal of the American Society of Clinical Oncology. 2006; 24:268-273.
26. Hou P, Liu D, Dong J, Xing M. The BRAF(V600E) causes widespread alterations in gene methylation in the genome of melanoma cells. Cell Cycle. 2012; 11:286-295.
27. Tessier-Lavigne M, Goodman CS. The molecular biology of axon guidance. Science. 1996; 274:1123-1133.
28. Santiago A, Erickson CA. Ephrin-B ligands play a dual role in the control of neural crest cell migration. Development. 2002; 129:3621-3632.
29. Kuriyama S, Mayor R. Molecular analysis of neural crest migration. Philosophical Transactions of the Royal Society of London Series, B, Biological Sciences. 2008; 363:1349-1362.
30. Yaar M, Park HY. Melanocytes: a window into the nervous system. The Journal of Investigative Dermatology. 2012; 132:835-845.
31. Van Aelst L, Cline HT. Rho GTPases and activitydependent dendrite development. Current Opinion in Neurobiology. 2004; 14:297-304.
32. Riento K, Ridley AJ. Rocks: multifunctional kinases in cell behaviour. Nature reviews Molecular Cell Biology. 2003; 4:446-456.
33. Kawauchi T. Cell Adhesion and Its Endocytic Regulation in Cell Migration during Neural Development and Cancer Metastasis. International Journal of Molecular Sciences. 2012; 13:4564-4590.
34. Noren NK, Pasquale EB. Eph receptor-ephrin bidirectional signals that target Ras and Rho proteins. Cellular Signalling. 2004; 16:655-666.
35. Egea J, Klein R. Bidirectional Eph-ephrin signaling during axon guidance. Trends in Cell Biology. 2007; 17:230-238.
36. Benson MD, Romero MI, Lush ME, Lu QR, Henkemeyer M, Parada LF. Ephrin-B3 is a myelin-based inhibitor of neurite outgrowth. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102:10694-10699.
37. Duffy P, Wang X, Siegel CS, Tu N, Henkemeyer M, Cafferty WB, Strittmatter SM. Myelin-derived ephrinB3 restricts axonal regeneration and recovery after adult CNS injury. Proceedings of the National Academy of Sciences of the United States of America. 2012; 109:5063-5068.
38. Nakamura F, Kalb RG, Strittmatter SM. Molecular basis of semaphorin-mediated axon guidance. Journal of Neurobiology. 2000; 44:219-229.
39. Hata K, Kaibuchi K, Inagaki S, Yamashita T. Unc5B associates with LARG to mediate the action of repulsive guidance molecule. The Journal of Cell Biology. 2009; 184:737-750.
40. Larrivee B, Freitas C, Trombe M, Lv X, Delafarge B, Yuan L, Bouvree K, Breant C, Del Toro R, Brechot N, Germain S, Bono F, Dol F, Claes F, Fischer C, Autiero M, et al. Activation of the UNC5B receptor by Netrin-1 inhibits sprouting angiogenesis. Genes & Development. 2007; 21:2433-2447.
41. Klagsbrun M, Eichmann A. A role for axon guidance receptors and ligands in blood vessel development and tumor angiogenesis. Cytokine & Growth Factor Reviews. 2005; 16:535-548.
42. Biankin AV, Waddell N, Kassahn KS, Gingras MC, Muthuswamy LB, Johns AL, Miller DK, Wilson PJ, Patch AM, Wu J, Chang DK, Cowley MJ, Gardiner BB, Song S, Harliwong I, Idrisoglu S, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012; 491:399-405.
43. Nasarre P, Potiron V, Drabkin H, Roche J. Guidance molecules in lung cancer. Cell Adhesion & Migration. 2010; 4:130-145.
44. Chedotal A, Kerjan G, Moreau-Fauvarque C. The brain within the tumor: new roles for axon guidance molecules in cancers. Cell Death and Differentiation. 2005; 12:1044-1056.
45. Argast GM, Croy CH, Couts KL, Zhang Z, Litman E, Chan DC, Ahn NG. Plexin B1 is repressed by oncogenic B-Raf signaling and functions as a tumor suppressor in melanoma cells. Oncogene. 2009; 28:2697-2709.
46. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, Paulovich A, Pomeroy SL, Golub TR, Lander ES, Mesirov JP. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102:15545-15550.
47. Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinformatics. 2011; 12:323.
48. Anders S, Huber W. Differential expression analysis for sequence count data. Genome Biology. 2010; 11:R106.